COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00343317
Recruitment Status : Completed
First Posted : June 22, 2006
Last Update Posted : June 22, 2006
Bristol-Myers Squibb
Information provided by:
University of KwaZulu

Brief Summary:

Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of postpartum complications than uninfected women. In South Africa, HIV/AIDS and related infections are now cumulatively the leading causes of maternal deaths (though indirectly), with puerperal sepsis among the 5 most common causes.

This was a prospective longitudinal cohort of HIV infected (n = 675) and uninfected (n = 648) women. These were women in whom vaginal delivery was anticipated, and were recruited at > 36 weeks of gestation during the antenatal period.

Hypothesis - HIV infected women are at increased risk of postpartum infectious morbidity and this morbidity can be reduced by use of prophylactic intrapartum antibiotics.

Condition or disease Intervention/treatment Phase
Puerperal Sepsis Drug: Intrapartum Cefoxitin (2g) vs. placebo Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 1372 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women
Study Start Date : February 2003
Study Completion Date : May 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. The primary outcome measure was the development of postpartum infectious morbidity amongst HIV infected versus HIV uninfected pregnant women.
  2. To determine the efficacy of intrapartum prophylactic antibiotics in reducing postpartum infectious morbidity in HIV infected women.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women with a pregnancy of > to 36 weeks of gestation
  • Women with known HIV status as documented by routine rapid HIV tests, following pre-test voluntary counselling and testing (VCT).
  • Women who gave informed study consent.
  • Over the age of 18years
  • Eligible for vaginal delivery

Exclusion Criteria:

  • Women who received antibiotic therapy less than 2 weeks prior to study enrolment.
  • Women planned for elective caesarean delivery.
  • Obstetric complications such as preterm prelabour rupture of membranes, cardiac disease, diabetes and antepartum haemorrhage.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00343317

Layout table for location information
South Africa
University of KwaZulu-Natal / King Edward VIII Hospital
Durban, KwaZulu-Natal, South Africa, 4013
Sponsors and Collaborators
University of KwaZulu
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: Hannah M Sebitloane, MBChB, FCOG University of KwaZulu
Layout table for additonal information Identifier: NCT00343317    
Other Study ID Numbers: RES112/02
First Posted: June 22, 2006    Key Record Dates
Last Update Posted: June 22, 2006
Last Verified: May 2005
Keywords provided by University of KwaZulu:
puerperal sepsis
HIV infection
prophylactic antibiotics
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Seropositivity
Systemic Inflammatory Response Syndrome
Pathologic Processes
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-Bacterial Agents
Anti-Infective Agents